Tscan Therapeutics Inc (TCRX) — Capital Reinvestment Ratio

Latest as of September 2023: 0.18x

Tscan Therapeutics Inc (TCRX) has a Capital Reinvestment Ratio of 0.18x as of September 2023, meaning it reinvests 0% of its operating cash flow ($8.02 Million) in capital expenditures ($1.42 Million). See Tscan Therapeutics Inc (TCRX) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.18x

Capex / Operating Cash Flow

Operating Cash Flow

$8.02 Million

USD

Capital Expenditures

$1.42 Million

USD

Data as of

Sep 2023

Most recent filing

Annual Capital Reinvestment Ratio for Tscan Therapeutics Inc (None–None)

Year-by-year Capital Reinvestment Ratio for Tscan Therapeutics Inc from None to None. For live market cap and broader valuation context, see Tscan Therapeutics Inc (TCRX) market capitalisation.

Year	Reinvestment Ratio	Operating CF (USD)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow